{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"limitationsAndCaveats":{"description":"Overall survival results are confounded by the fact that 85% of the participants initially randomized to placebo switched to open-label regorafenib."},"pointOfContact":{"email":"clinical-trials-contact@bayer.com","organization":"BAYER","title":"Therapeutic Area Head"}}